The economic benefits of acetylcholinesterase inhibitors for patients with alzheimer disease and associated dementias

Alzheimer Disease and Associated Disorders

Volumn 18, Issue SUPPL. 1, 2004, Pages

  Fillit, Howard ^a   Hill, Jerrold ^a  

^a Alzheimers Drug Discovery Foundation   (United States)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer disease; Pharmacoeconomics outcomes

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; RIVASTIGMINE;

ALZHEIMER DISEASE; CAREGIVER; COGNITION; COMORBIDITY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DEMENTIA; DRUG COST; DRUG EFFICACY; HEALTH CARE UTILIZATION; HUMAN; INSTITUTIONAL CARE; MEDICARE; OUTCOMES RESEARCH; PRIORITY JOURNAL; UTILIZATION REVIEW;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COST OF ILLNESS; COST SAVINGS; DRUG COSTS; HEALTH EXPENDITURES; HOMES FOR THE AGED; HOSPITALIZATION; HUMANS; NOOTROPIC AGENTS; NURSING HOMES; SELF CARE; UNITED STATES;

EID: 2942619983     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wad.0000127492.65032.d3     Document Type: Conference Paper

References (52)

1. Evans DA. Estimated prevalence of Alzheimer's disease in the United States. Milbank Q. 1990;68:267-289.
2. Fox PJ, Kohatsu N, Max W, et al. Estimating the costs of caring for people with Alzheimer disease in California: 2000-2040. J Public Health Policy. 2001;22:88-97.
3. Beeri MS, Werner P, Davidson M, et al. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry. 2002;17:403-408.
4. Lamb HM, Goa KL. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease. Pharmacoeconomics. 2001;19:303-318.
5. Trabucchi M. An economic perspective on Alzheimer's disease. J Geriatr Psychiatry Neurol. 1999;12:29-38.
6. Hux MJ, O'Brien BJ, Iskedjian M, et al. Relation between severity of Alzheimer's disease and costs of caring. CMAJ 1998;159:457-465.
7. Beeri MS, Werner P, Adar Z, et al. Economic cost of Alzheimer disease in Israel. Alzheimer Dis Assoc Disord. 2002;16:73-80.
8. Taylor DH Jr, Sloan FA. How much do persons with Alzheimer's disease cost Medicare? J Am Geriatr Soc. 2000;48:639-646.
9. Fishman P, Von Korff M, Lozano P, et al. Chronic care costs in managed care. Health Aff. 1997;16:239-247.
10. Weiner M, Powe NR, Weller WE, et al. Alzheimer's disease under managed care: implications from Medicare utilization and expenditure patterns. J Am Geriatr Soc. 1998;46:762-770.
11. Gutterman EM, Markowitz JS, Lewis B, et al. Cost of Alzheimer's disease and related dementia in managed-medicare. J Am Geriatr Soc. 1999;47:1065-1071.
12. Menzin J, Lang K, Friedman M, et al. The economic cost of Alzheimer's disease and related dementias to the California Medicaid program ("Medí-Cal") in 1995. Am J Geriatr Psychiatry. 1999;7:300-308.
13. Leon J, Neumann PJ. The cost of Alzheimer's disease in managed care: a cross-sectional study. Am J Manag Care. 1999;5:867-877.
14. Hill JW, Futterman R, Duttagupta S, et al. Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare. Neurology. 2002;58:62-70.
15. Torian L, Davidson E, Fulop G, et al. The effect of dementia on acute care in a geriatric medical unit. Int Psychogeriatr. 1992;4:231-239.
16. Albert SM, Costa R, Merchant C, et al. Hospitalization and Alzheimer's disease: results from a community-based study. J Gerontol A Biol Sci Med Sci. 1999;54:M267-M271.
17. Fillit H, Hill JW, Fufferman R. Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy. Fam Med. 2002;34:528-535.
18. Doraiswamy PM, Leon J, Cummings JL, et al. Prevalence and impact of medical comorbidity in Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 2002;57:M173-M177.
19. Fillit HM. The pharmacoeconomics of Alzheimer's disease. Am J Manag Care. 2000;6:S1139-S1144.
20. Fillit H, Gutterman EM, Lewis B. Donepezil use in managed Medicare: effect on health care costs and utilization. Clin Ther. 1999;21:2173-2185.
21. Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer's disease. Clin Ther. 1998;20:838-850.
22. Hill JW, Futterman R, Mastey V, et al. The effect of donepezil therapy on health costs in a medicare managed care plan. Manag Care Interface. 2002;15:63-69.
23. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ. 2000;321:1445-1449.
24. Rockwood K, Mintzer J, Truyen L, et al. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2001;71:589-595.
25. Morris JC, Truyen I. Galantamine produces long-term cognitive benefits in patients with Alzheimer's disease (AD) [abstract]. J Am Geriatr Soc. 2002;50(suppl):S25.
26. Truyen L, Lilienfeld S, Kershaw P. Safety and efficacy of galantamine in Alzheimer's disease after treatment for 4 years. Poster presented at: Alzheimer's Disease International 18th Annual Conference; October 23-26, 2002: Barcelona, Spain.
27. Ernst RL, Hay JW, Fenn C, et al. Cognitive function and the costs of Alzheimer disease. An exploratory study. Arch Neurol. 1997;54:687-693.
28. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;12:397-409.
29. Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil. Int J Geriatr Psychiatry. 1998;13:445-453.
30. Jonsson L, Lindgren P, Wimo A, et al. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clin Ther. 1999;21:1230-1240.
31. O'Brien BJ, Goeree R, Hux M, et al. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc. 1999;47:570-578.
32. Lanctôt KL, Risebrough N, Oh PI. Factors affecting the economic attractiveness of cognitive enhancers in Alzheimer's disease [abstract]. J Clin Pharmacol. 1998;38:584.
33. Ikeda S, Yamada Y, Ikegami N. Economic evaluation of donepezil treatment for Alzheimer's disease in Japan. Dement Geriatr Cogn Disord. 2002;13:33-39.
34. Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology. 1999;52:1138-1145.
35. Fenn P, Gray A. Estimating long-term cost savings from treatment of Alzheimer's disease. A modelling approach. Pharmacoeconomics. 1999;16:165-174.
36. Brooks E, Deal L. The effect of rivastigmine on the direct and indirect costs of Alzheimer's disease [abstract]. Value Health. 2000;3:79.
37. Hauber AB, Gnanasakthy A, Mauskopf JA. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine. Clin Ther. 2000;22:439-451.
38. Hauber AB, Gnanasakthy A, Snyder EH, et al. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine. Pharmacoeconomics. 2000;17:351-360.
39. Caro JJ, Getsios D, Migliaccio-Walle K, et al. Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care. Neurology. 2001;57:964-971.
40. Stern Y, Tang MX, Albert MS, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA. 1997;277:806-812.
41. Stern Y, Folstein M, Albert M, et al. Multicenter study of predictors of disease course in Alzheimer disease (the "predictors study"). I. Study design, cohort description, and intersite comparisons. Alzheimer Dis Assoc Disord. 1993;7:3-21.
42. Getsios D, Caro JJ, Caro G, et al. Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada. Neurology. 2001;57:972-978.
43. Garfield FB, Getsios D, Caro JJ, et al. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in Sweden. Pharmacoeconomics. 2002;20:629-637.
44. Caro JJ, Salas M, Ward A, et al. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands. Dement Geriatr Cogn Disord. 2002;14:84-89.
45. Migliaccio-Walle K, Getsios D, Caro JJ, et al. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clin Ther. 2003;25:1806-1825.
46. Taylor DH Jr, Schenkman M, Zhou J, et al. The relative effect of Alzheimer's disease and related dementias, disability, and comorbidities on cost of care for elderly persons. J Gerontol B Psychol Sci Soc Sci. 2001;56: S285-S293.
47. Wolstenholme J, Fenn P, Gray A, et al. Estimating the relationship between disease progression and cost of care in dementia. Br J Psychiatry. 2002;181:36-42.
48. Jonsson L, Jonsson B, Wimo A, et al. Second International Pharmacoeconomic Conference on Alzheimer's Disease. Alzheimer Dis Assoc Disord. 2000;14:137-140.
49. Winblad B, Wimo A. Assessing the societal impact of acetylcholinesterase inhibitor therapies. Alzheimer Dis Assoc Disord. 1999;13(suppl 2): S9-19.
50. Small GW, McDonnell DD, Brooks RL, et al. The impact of symptom severity on the cost of Alzheimer's disease. J Am Geriatr Soc. 2002;50:321-327.
51. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health. 1994;84:1261-1264.
52. Leon J, Cheng CK, Neumann PJ. Alzheimer's disease care: costs and potential savings. Health Aff. 1998;17:206-216.